Special Issue

Microbial Biofilms: Identification, Resistance and Novel Drugs

Message from the Guest Editors

Biofilms are the main growing form of microorganisms. These communities can be developed in both biological and nonliving surfaces, forming complex “cities”, protected from environmental agressions. Unfortunately, they also carry tolerance and resistance mechanisms to drugs which difficult their irradiation. The emergent threat of antimicrobial resistance (AMR) among bacterial, fungal or viral infections has driven the research community to explore effective alternatives to fight these critical pathogens. In this SI, we plan to explore in a deeper way, the potential bioactive effects of novel compounds to treat infections related to bacteria, fungi, viruses and parasites, with a particular interest in those directly related to AMR issues.

Guest Editors

Dr. Célia Fortuna Rodrigues

1. Associate Laboratory i4HB—Institute for Health and Bioeconomy, University Institute of Health Sciences—CESPU, 4585-116 Gandra, Portugal
2. ALiCE—Associate Laboratory in Chemical Engineering, Faculty of Engineering, LEPABE—Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Porto, Portugal

Dr. Susana Patrícia Lopes

CEB-Centre of Biological Engineering, LIBRO-Laboratory of Research in Biofilms Rosário Oliveira, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal

Deadline for manuscript submissions

15 December 2024

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed

mdpi.com/si/207003

Antibiotics
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI